JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 6
DOI:10.33266/1024-6177-2025-70-6-12-19
A.A. Melnikova1, 2, A.A. Afonin1, L.N. Komarova1
Integrative Analysis of Pmaip1 and Birc5 Gene Expression, as Well as Protein-Protein Interactions in Sk-N-Be(2) Neuroblastoma Cells in Combination Therapy
1 National Research Nuclear University MEPhI, Obninsk, Russia
2 A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia
Contact person: A.A. Melnikova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Evaluation of the effect of ionizing radiation with various linear energy transfer on the expression of the PMAIP1 (Noxa) and BIRC5 (Survivin) genes to elucidate the molecular mechanisms determining the radiosensitivity of tumor cells.
Material and methods: The object of the study was SK-N-BE(2) cells. Four study groups were formed: a group exposed to ionizing radiation; a group treated with doxorubicin; a group of combined exposure to ionizing radiation and doxorubicin; and an untreated control group.
The cells were irradiated with 12C ions at the U-70 accelerator of the Institute for High Energy Physics (IHEP) of the National Research Centre «Kurchatov Institute» (Protvino, Moscow Region).
The irradiation was carried out at a dose of 4 Gy in an aqueous phantom with an average energy of 455 MeV/nucleon. The average LET of radiation in the initial phase was 11 keV/µm, with a peak of 120‒140 keV/µm. The cells were also irradiated with gamma radiation on the basis of the Russian Institute of Radiology and Agroecology at the unique scientific facility «Gamma radiation irradiation unit GUR-120» (radiation source 60Co, 1.25 MeV) at a dose of 4 Gy. The dose rate was 0.9 Gy /min. The cells were treated with the chemotherapy drug doxorubicin at a concentration of 0.004 mg/ml 24 hours before irradiation. Total RNA was isolated using an RNA Solo kit and quantified spectrophotometrically (NanoDrop ND-1000). Reverse transcription and amplification were performed simultaneously in real time using the OneTube RT-PCR kit with SYBR Green I as a fluorescent indicator. Key regulatory targets were identified from a set of common targets using STRING (protein-protein interaction network analysis, Homo sapiens), visualized and analyzed in Cytoscape v3.10.3 (CytoHubba plugin), and functionally annotated using Metascape (GO and KEGG pathway analysis, p<0,01).
Results: In SK-N-BE(2) cells, doxorubicin demonstrated a significant decrease in the expression of the BIRC5 gene, which is consistent with its known proapoptotic activity. The combined effect of gamma radiation (4 Gy) and doxorubicin demonstrated an additive effect (0,04). Irradiation with 12C ions demonstrated a significant decrease in BIRC5 expression with monotherapy (0,02), but a less pronounced decrease in the case of combined action with doxorubicin (0,10). Doxorubicin induced the expression of the PMAIP1 gene (0.16), this effect was synergistically enhanced when combined with gamma radiation (0.25), but was suppressed when using 12C ions (0.05), which is probably due to the activation of antiapoptotic mechanisms.
Conclusion: The results of the analysis of Gene Ontology and gene expression in SK-N-BE(2) cells confirmed the functional specialization of PMAIP1 (mitochondrial apoptosis) and BIRC5 (cell cycle regulation). Doxorubicin and gamma radiation enhanced apoptosis by affecting these genes, while 12C ions activated DNA repair, suppressing PMAIP1 and weakening the effect on BIRC5.
Keywords: 12C ion radiation therapy, gamma therapy, Bcl-2 family proteins, SK-N-BE (2), doxorubicin, BIRC5, PMAIP1, gene ontology
For citation: Melnikova AA, Afonin AA, Komarova LN. Integrative Analysis of Pmaip1 and Birc5 Gene Expression, as Well as Protein-Protein Interactions in Sk-N-Be(2) Neuroblastoma Cells in Combination Therapy. Medical Radiology and Radiation Safety. 2025;70(6):12–19. (In Russian). DOI:10.33266/1024-6177-2025-70-6-12-19
References
1. Roufayel R., Younes K., Al-Sabi A., Murshid N. BH3-Only Proteins Noxa and Puma Are Key Regulators of Induced Apoptosis. Life (Basel). 2022;12;2:256. doi:10.3390/life12020256.
2. Greaves G., Milani M., Butterworth M., Carter R.J., Byrne D.P., Eyers P.A., Luo X., Cohen G.M., Varadarajan S. BH3-Only Proteins Are Dispensable for Apoptosis Induced by Pharmacological Inhibition of Both MCL-1 and BCL-X L. Cell Death Differ. 2019;26:1037-1047. doi: 10.1038/s41418-018-0183-7.
3. Huang K., O’Neill K.L., Li J., Zhou W., Han N., Pang X., Wu W., Struble L., Borgstahl G., Liu Z. BH3-Only Proteins Target BCL-XL/MCL-1, Not BAX/BAK, to Initiate Apoptosis. Cell Res. 2019;29:942-952. doi: 10.1038/s41422-019-0231-y.
4. Rafatmanesh A., Behjati M., Mobasseri N., Sarvizadeh M., Mazoochi T., Karimian M. The Survivin Molecule as a Double-Edged Sword in Cellular Physiologic and Pathologic Conditions and its Role as a Potential Biomarker and Therapeutic Target in Cancer. J Cell Physiol. 2020;235;2:725-744. doi:10.1002/jcp.29027.
5. George R., Hehlgans S., Fleischmann M., Rödel C., Fokas E., Rödel F. Advances in Nanotechnology-Based Platforms for Survivin-Targeted drug Discovery. Expert Opin Drug Discov. 2022;17;7:733-754. doi:10.1080/17460441.2022.2077329.
6. Wijaya W., Phyu S.M., Jiang S. Extracellular Vesicle (EV) Survivin for Cancer Diagnostics and Therapeutics: A Review. Front Biosci (Landmark Ed). 2024;29;8:302. doi:10.31083/j.fbl2908302.
7. Liao J., Qing X., Li X., et al. TRAF4 Regulates Ubiquitination-Modulated Survivin Turnover and Confers Radioresistance. Int J Biol Sci. 2024;20;1:182-199. doi:10.7150/ijbs.87180.
8. Fang X.L., Cao X.P., Xiao J., et al. Overview of Role of Survivin in Cancer: Expression, Regulation, Functions, and its Potential as a Therapeutic Target. J Drug Target. 2024;32;3:223-240. doi:10.1080/1061186X.2024.2309563.
9. Martínez-Sifuentes M.A., Bassol-Mayagoitia S., Nava-Hernández M.P., et al. Survivin in Breast Cancer: A Review. Genet Test Mol Biomarkers. 2022;26;9:411-421. doi:10.1089/gtmb.2021.0286.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. A.A. Melnikova – conducting experiments, research development; A.A. Afonin – conducting experiments; L.N. Komarova – development of the research concept, scientific supervision.
Article received: 20.07.2025. Accepted for publication: 25.08.2025.